The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
Dose escalation safety study
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
54
This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
Pfizer Investigational Site
Beverly Hills, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
To determine the safety and tolerability of PF-04523655 when administered as a single intravitreal injection
Time frame: Over a 24-Month Period
To describe anatomical changes in the retina and choroid following the administration of PF-04523655
Time frame: Day 14
To determine the changes in visual acuity ETDRS chart after a single intravitreal injection of PF-04523655
Time frame: Day 14
To evaluate the safety, efficacy and frequency of dosing following administration of PF-04523655 of approved VEGF-inhibitors in those study patients requiring rescue therapy
Time frame: Monthly
To evaluate early response after a single intravitreal administration of PF-04523655 in patients who, in the opinion of the investigator, have the potential to show improvement in visual acuity from other treatment options (Stratum 2 patients)
Time frame: Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
‘Aiea, Hawaii, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Tel Aviv, Israel, Israel
Pfizer Investigational Site
Petah Tikva, Israel
...and 1 more locations